Revenue
2012
2013
2021
2022
2023
2024
2025
Medicinova Inc (MNOV)
Price$1.63Cached quote
Net income
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $409,657 | $0 | $1.0M | $0 | $4.0M | — | — | — | — | — | — | — | $3,257 | $802,580 | — | — | — | — | — | — | — |
| Research & development | $6.7M | $6.8M | $5.3M | $8.7M | $8.1M | $7.1M | $5.7M | $5.3M | $3.9M | $3.1M | $2.7M | $2.9M | $2.7M | $4.5M | $7.8M | $9.7M | $10.9M | — | — | — | — |
| Operating expenses | $13.7M | $12.7M | $10.9M | $14.6M | $14.3M | $14.2M | $14.0M | $15.6M | $13.0M | $10.9M | $8.8M | $9.2M | $10.0M | $11.7M | $16.1M | $17.9M | $21.2M | — | — | — | — |
| Operating income | −$13.3M | −$12.7M | −$9.9M | −$14.6M | −$10.2M | −$14.2M | −$14.0M | −$15.6M | −$13.0M | −$10.9M | −$8.8M | −$9.2M | −$4.0M | −$10.9M | −$16.1M | −$17.9M | −$21.2M | — | — | — | — |
| Operating margin | −3,242.47% | — | −990.03% | — | −253.02% | — | — | — | — | — | — | — | −123,443.05% | −1,363.77% | — | — | — | — | — | — | — |
| EBITDA | −$13.3M | −$12.7M | −$9.9M | −$14.6M | −$10.2M | −$14.2M | −$14.0M | −$15.6M | −$13.0M | −$10.9M | −$8.8M | −$9.2M | −$3.9M | −$10.9M | −$16.1M | −$17.8M | −$21.0M | — | — | — | — |
| EBITDA margin | −3,237.56% | — | −988.00% | — | −252.38% | — | — | — | — | — | — | — | −120,357.78% | −1,355.11% | — | — | — | — | — | — | — |
| Net income | −$12.0M | −$11.0M | −$8.6M | −$14.1M | −$10.1M | −$13.9M | −$12.9M | −$14.7M | −$11.2M | −$10.9M | −$8.8M | −$9.2M | −$4.0M | −$11.0M | −$17.7M | −$20.2M | −$20.4M | −$21.9M | −$48.9M | −$35.7M | −$25.7M |
| Net profit margin | −2,928.78% | — | −857.15% | — | −251.00% | — | — | — | — | — | — | — | −123,688.30% | −1,365.76% | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.24 | -$0.23 | -$0.17 | -$0.29 | -$0.21 | -$0.31 | -$0.30 | -$0.36 | -$0.32 | -$0.33 | -$0.33 | -$0.38 | -$0.19 | -$0.66 | -$1.20 | -$1.63 | -$1.68 | — | — | — | — |
| Diluted EPSper diluted share | -$0.24 | -$0.23 | -$0.17 | -$0.29 | -$0.21 | -$0.31 | -$0.30 | -$0.36 | -$0.32 | -$0.33 | -$0.33 | -$0.38 | -$0.19 | -$0.66 | -$1.20 | -$1.63 | -$1.68 | — | — | — | — |
Owners
Reported shareholders
2.25%of listed shares
Essex Woodlands Management, Inc.1.11M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Essex Woodlands Management, Inc. | 2.25%1.11M shares |
BlackRock, Inc. | 1.53%752.09K shares |
CITIGROUP INC | 1.29%635.72K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.24%609.05K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.10%539.31K shares |
VANGUARD FIDUCIARY TRUST CO | 0.57%282.61K shares |
UBS Group AG | 0.45%222.2K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.42%205.4K shares |
STATE STREET CORP | 0.39%193.7K shares |
NORTHERN TRUST CORP | 0.29%143.67K shares |
Bank of New York Mellon Corp | 0.16%78.28K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.15%71.51K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.11%56.03K shares |
SBI Securities Co., Ltd. | 0.10%51.48K shares |
DIMENSIONAL FUND ADVISORS LP | 0.10%50.55K shares |
BARCLAYS PLC | 0.09%42.81K shares |
Schonfeld Strategic Advisors LLC | 0.07%36.16K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.05%26.75K shares |
JANE STREET GROUP, LLC | 0.03%15.82K shares |
Vanguard Global Advisers, LLC | 0.03%15.6K shares |
Percentages use 49.22M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data